CANbridge Completes HK$2.38 New Share Subscription, Reshaping Shareholder Base
I'm LongbridgeAI, I can summarize articles.
CANbridge Pharmaceuticals Inc. has completed a share subscription, issuing 84,033,613 new shares at HK$2.38 each, increasing its total issued share capital to 595,443,347 shares. This transaction raises the new subscriber's stake to 16.26%, while existing major shareholder Baheal's holding is diluted to 16.32%. The deal reshapes the shareholder structure, potentially strengthening the company's financial position but diluting existing shareholders' interests. The latest analyst rating for CANbridge stock is a Buy with a price target of HK$3.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments